Five abstracts accepted for poster presentations 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company focused on infectious disease have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10 The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies Unapproved Therapies or Strategies session on May 8 Abstract Number: 1768Title: IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therapyPresenter: Prof 2025Key Findings: Within this small group of subjects who achieved functional cure or HBV DNA<LLOQ after NA discontinuation in the IM-PROVE I study HBsAg at baseline and at the time of NA discontinuation appear to be the only factors associated with functional cure with no apparent differences in other baseline characteristics or HBV biomarkers collected Additional analysis of this dataset is ongoing and the potential association of baseline characteristics and HBV biomarkers with functional cure should continue to be evaluated in larger trials This will also be featured in the Poster Tour: Viral Hepatitis Abstract Number: 2043Title: IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis Bsubjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearancePresenter: Dr 2025Key Findings: Subjects who achieved functional cure after combination treatment with imdusiran plus interferon showed rapid HBV RNA decline during imdusiran lead-in with 5 of 6 subjects achieving HBV RNA undetectability during this period Transient elevations in HBV RNA were observed to occur during the interferon treatment period which was associated with further HBsAg decline and loss in some functional cure subjects Abstract Number: 1990Title: First-in-human pharmacokinetics and pharmacodynamics of oral small-moleculePD-L1 inhibitor AB-101 and correlation to preclinical modelsPresenter: Dr 2025Key Findings: AB-101 was safe and well-tolerated in both single- and multiple-dose administrations in healthy subjects Dose-responsive increases in PD-L1 receptor occupancy were observed in peripheral blood cells which correlated with dose-dependent increases in AB-101 plasma concentrations The clinical plasma PK profile of AB-101 to date indicates rapid distribution into tissues mirroring the plasma profiles seen in preclinical efficacy models which exhibited high liver biodistribution and target engagement Abstract Number: 1978Title: Preliminary safety pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101 in healthy and chronic hepatitis B subjectsPresenter: Prof 2025Key Findings: Single doses of AB-101 up to 40 mg and repeat doses up to 40 mg QD for 7 days were well tolerated in healthy subjects Preliminary PD data shows AB-101 receptor occupancy at doses ≥ 10 mg with dose-responsive increases in PD-L1 receptor occupancy observed Dosing in Part 3 in CHB subjects is ongoing and available data including receptor occupancy and HBV virologic biomarkers The following late-breaker poster will be presented on May 7 Abstract Number: LB25153Title: Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed non-cirrhotic subjects with chronic hepatitis B (CHB)Presenter: Dr Imdusiran is an RNAi therapeutic specifically designed to reduce all HBV viral proteins and antigens including hepatitis B surface antigen which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus Imdusiran targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology enabling subcutaneous delivery imdusiran achieved meaningful functional cure rates in patients with cHBV when combined with pegylated interferon (IFN) alfa-2α and nucleos(t)ide analogue (NA) therapy Clinical data generated thus far has shown imdusiran to be generally safe and well-tolerated while also providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA The Company is currently reviewing development plans for a Phase 2b clinical trial of imdusiran combined with IFN and NA therapy AB-101 is an oral PD-L1 inhibitor candidate that is designed to allow for controlled immune checkpoint blockade while minimizing the systemic safety issues typically seen with immune checkpoint antibody therapies Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation Preclinical data generated thus far indicates that AB-101 mediates re-activation of exhausted HBV-specific T-cells from cHBV patients AB-101 is currently being evaluated in a Phase 1a/1b clinical trial Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV) HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer Chronic HBV infection represents a significant unmet medical need The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection while other estimates indicate that approximately 2 million people in the United States suffer from chronic HBV infection Approximately 1.1 million people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options Forward-Looking Statements and Information This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and forward-looking information within the meaning of Canadian securities laws (collectively Forward-looking statements in this press release include statements about: the potential to lead to a functional cure for HBV; the result of Arbutus’ review of its pipeline and development plans for its cHBV programs and the potential for Arbutus’ product candidates to achieve success in clinical trials With respect to the forward-looking statements contained in this press release Arbutus has made numerous assumptions regarding among other things: the effectiveness and timeliness of clinical trials and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus’ assets; and the stability of economic and market conditions While Arbutus considers these assumptions to be reasonable these assumptions are inherently subject to significant business market and social uncertainties and contingencies there are known and unknown risk factors which could cause Arbutus’ actual results performance or achievements to be materially different from any future results performance or achievements expressed or implied by the forward-looking statements contained herein among others: ongoing and anticipated clinical trials may be more costly or take longer to complete than anticipated or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; and market shifts may require a change in strategic focus All forward-looking statements herein are qualified in their entirety by this cautionary statement and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results Officials identified the officer who fatally shot a man in Arbutus on Wednesday as a 28-year veteran of the Baltimore County Police Department Detective Todd Weidel is the officer who fatally shot Arvel Jones Sr., 51, in Arbutus after reports that he was shooting arrows at passing cars, the Maryland attorney general’s office announced Investigators said Jones donned a black ski mask wielded a bow-and-arrow and fired it at passing cars on Wednesday Weidel and another officer separately responded to a call about Jones’ actions around 10:30 a.m Weidel was not equipped with a body-worn camera The other officer did not activate his body-worn camera until after the incident The Baltimore Banner thanks its sponsors. Become one. Officials said Weidel and the other officer provided aid until EMS arrived to bring Jones to the hospital Weidel has been with the Baltimore County Police Department for 28 years according to the attorney general’s office Jones’ son, Arvel Jones Jr., told WJZ-TV his father was likely having a mental health episode but that he was a nonviolent man who “wouldn’t hurt a fly.” but that doesn’t make it right for you to take his life,” Arvel Jones Jr Jones’ shooting rattled the small Arbutus community where movement and classes continued as the outside was secured Neighbors sat in shock at the incident happening so close to their home WJZ is a media partner of The Baltimore Banner Darreonna Davis darreonna.davis@thebaltimorebanner.com Darreonna Davis is an express desk reporter at The Baltimore Banner She previously reported at the intersection of gender health and economic policy as a fellow for the 19th News Welcome to The Banner's subscriber-only commenting community. Please review our community guidelines Use of this site constitutes acceptance of our Terms of Service and Privacy Policies The Baltimore Banner is a trademark registered in the U.S for The Venetoulis Institute for Local Journalism Welcome to The Banner's subscriber-only commenting community. Please review our community guidelines Use of this site constitutes acceptance of our Terms of Service and Privacy Policies Click here to view our Terms of Sale.\n \n Click here to learn more about supporting local journalism.\n Something went wrong. Please try again in a few minutes. If the problem persists, please contact customer service at 443-843-0043 or customercare@thebaltimorebanner.com — We're learning more of what led to a deadly police involved shooting in Arbutus Wednesday According to the Maryland Attorney General's Office officers were called to the 5100 block of Leeds Avenue for reports of a masked man shooting at passing cars with a bow and arrow When Baltimore County Police arrived on scene around 10:30am they encountered a suspect meeting the description provided by the 911 caller While it's unclear what transpired from there RELATED: Man reportedly armed with bow and arrow shot and killed by police in Arbutus The Attorney General's Independent Investigative Division is handling the deadly force aspect of the case meaning portions of the incident were captured on video which could be released sometime in the next couple weeks Please select what you would like included for printing: Copy the text below and then paste that into your favorite email application but her spirit will live on in the hearts of all who knew and loved her her personality radiating warmth that embraced everyone around her Her humor was a gift that she shared generously; it brought joy to gatherings and laughter to conversations ultimately creating a legacy of care and compassion that will be felt for generations She shared profound bonds with her children and reveled in the love of her cherished grandson Arbutus’s life was enriched by her deep connection to her siblings: Nellie Russo Foisy of Lorain and created memories that will forever echo in their hearts Arbutus found joy in crocheting intricate patterns often sharing those hours with her beloved great nieces infusing her family gatherings with delicious aromas and flavorful dishes that left lasting impressions Arbutus could often be found singing her favorite songs her voice bringing warmth and familiarity to those who listened They will undoubtedly welcome her with open arms as she brings her characteristic humor and loving spirit to the heavens Arbutus Russo Comstock’s impact on this world cannot be measured; she was a true embodiment of love Her memory will continue to shine brightly through the stories shared and the love passed down through the generations she touched Though she has departed from this earthly realm her spirit will forever remain a guiding force for all those who cherished her Funeral arrangements entrusted to Slone & Co This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply Service map data © OpenStreetMap contributors iStock, Andry Djumantara Arbutus Biopharma is letting go of 57% of its staff bringing the Pennsylvania biotech down to a “core team” of 19 employees who will focus on its hepatitis B program according to a press announcement on Thursday Arbutus is also terminating all in-house scientific research and will leave its corporate headquarters in Warminster the biotech expects to absorb one-time costs of around $11 million to $13 million in the first quarter Arbutus is also thinning out its masthead: chief financial officer David Hastings chief medical officer Karen Sims and chief compliance officer Christopher Naftzger will all be stepping down from their leadership roles It is unclear how much Arbutus expects to save from these strategic moves but CEO Lindsay Androski noted in a statement on Thursday that they will help “improve our financial and operational efficiency.” Arbutus on Thursday named Tuan Nguyen as its new CFO whose appointment “reinforces our renewed focus on advancing our pipeline efficiently and delivering value to patients and our stakeholders,” Androski said Arbutus is “reviewing development plans” for pushing imdusiran into Phase IIb including looking for ways to potentially accelerate its timeline Arbutus is also working on an oral PD-L1 blocker which it is developing for chronic hepatitis B The asset is currently in a Phase Ia/Ib trial that is mostly assessing its safety and tolerability The biotech has moved forward with the third part of this early study It has yet to disclose next steps for the asset cash equivalents and marketable securities down from a cash position of $132.3 million the year prior the biotech “expects to significantly reduce its net cash burn” this year though it did not provide guidance on how long it expects its runway to last 2025 at 12:50 pm ET.css-79elbk{position:relative;}Authorities have released the name of a man armed with a bow and arrow who was fatally shot Wednesday by Baltimore County police along with the name of the officer who fired the shot MD — The name of a man armed with a bow and arrow who was fatally shot Wednesday in Arbutus by Baltimore County police — sparking brief lockouts at three nearby schools — was released Friday by officials of Arbutus died at an area hospital after he was confronted by police officers in the 5100 block of Leeds Avenue around 10:25 a.m The Independent Investigations Division of the Maryland Office of the Attorney General released the name of Jones and the officer who fired at him The Baltimore County Police Department said Detective Todd Wiedel a 28-year veteran of the department assigned to the Operations Bureau "During this encounter, officers responded to the actions of the armed subject, resulting in one detective discharging his firearm, striking the adult male," the Baltimore County Police Department said in a press release Officers said they immediately administered life-saving measures to Jones Arbutus Middle School and Maiden Choice School were briefly put on lockout status Arbutus Elementary Principal Samantha Maile said the lockout started around 10:30 a.m after "our Safety Manager made us aware of an individual in the community who was shooting a crossbow," and ended within 10 minutes no one can enter or leave the building without the principal’s permission Entry to or exit from a building is granted on a case-by-case basis and usually in conjunction with the Baltimore County Police Department," Maile wrote in a letter to families The IID continues to investigate the fatal officer-involved shooting. Anyone with information about this incident, including cell phone or private surveillance video, is asked to contact the IID at (410) 576-7070 or by email at IID@oag.state.md.us. Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts. We are learning more about the man shot and killed by police in Baltimore County. The Independent Investigations Division says the officer who fatally shot a man armed with a bow and arrow in Arbutus on Wednesday was not equipped with a body-worn camera Police responded to the 5100 block of Leeds Avenue after neighbors reported a man wearing a ski mask and carrying a bow and arrow Two officers were dispatched to the scene and approached the suspect According to the Maryland Attorney General’s Office the man’s actions prompted one of the officers to open fire Officials confirmed that the officer who fired the fatal shot was not wearing a body camera and the other officer’s camera was not activated until after the incident The man was later pronounced dead at the hospital The Independent Investigations Division is asking anyone with video footage of the incident to contact their office and the flagship stations for the Baltimore Ravens Hearst Television participates in various affiliate marketing programs which means we may get paid commissions on purchases made through our links to retailer sites.©2023 on behalf of WBAL NewsRadio 1090 and FM 101.5 Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer cash equivalents and investments in marketable securities of $123M today reported fourth quarter and year end 2024 financial results and provided a corporate update “With my recent appointment as CEO of Arbutus I am excited to lead the company into its next chapter,” said Lindsay Androski my focus is on evaluating strategies to accelerate the development and potential approval of imdusiran alongside several subject matter experts being retained to assist with this evaluation we have implemented a reduction in our workforce of 57% retaining a core team well-positioned to advance imdusiran into a Phase 2b trial and have taken additional related steps to improve our financial and operational efficiency We will provide an update on our pipeline and development timeline upon completion of our review of our chronic hepatitis B virus (cHBV) programs.” “I am also excited to welcome Tuan Nguyen to our leadership team as Chief Financial Officer Tuan’s appointment reinforces our renewed focus on advancing our pipeline efficiently and delivering value to patients and our stakeholders the Company announced today the departure of David Hastings and I would like to thank them for their valuable contributions over the past years We will continue to consult closely with and support our exclusive licensee Genevant Sciences to protect and defend our intellectual property including through recently filed international lawsuits against Moderna for patent infringement in the development of its COVID-19 and RSV vaccines We expect 2025 to be a transformative year for Arbutus.” cash equivalents and investments in marketable securities of $122.6 million compared to $132.3 million as of December 31 the Company used $64.9 million in operating activities which was partially offset by $44.1 million of net proceeds from the issuance of common shares under its “at-the-market” (ATM) offering program and $7.5 million of proceeds from the exercise of employee stock options The Company expects to significantly reduce its net cash burn in 2025 when compared to 2024 Given the Company’s review of its pipeline and development plans for its cHBV programs and refocused operations the Company has terminated its ATM offering program Total revenue was $6.2 million for the year ended December 31 compared to $18.1 million for the same period in 2023 The decrease of $11.9 million was due primarily to a $9.3 million decrease in revenue recognition of the upfront license fee received in 2022 from Qilu the Company’s collaboration partner in China as less effort was required from the Company in 2024 compared to 2023 to support Qilu’s progress towards achieving its own imdusiran manufacturing capability license royalty revenues decreased $2.6 million in 2024 compared to 2023 due to a decrease in Alnylam’s sales of ONPATTRO Research and development expenses were $54.0 million for the year ended December 31 2024 compared to $73.7 million for the same period in 2023 which included ceasing all discovery efforts discontinuing its IM-PROVE III clinical trial and reducing its workforce by 40% These actions in August 2024 resulted in the Company incurring a one-time restructuring charge of $3.7 million in the third quarter of 2024 General and administrative expenses were $22.1 million for the year ended December 31 compared to $22.5 million for the same period in 2023 This decrease was due primarily to decreases in employee compensation-related expenses partially offset by an increase in litigation-related legal fees or a loss of $0.38 per basic and diluted common share as compared to a net loss of $72.8 million or a loss of $0.44 per basic and diluted common share the Company had 190.0 million common shares issued and outstanding as well as 16.9 million stock options and unvested restricted stock units outstanding owned approximately 20% of the Company’s outstanding common shares as of December 31 The Company is currently reevaluating plans for a Phase 2b clinical trial of imdusiran combined with IFN and NA therapy AB-101 is an oral PD-L1 inhibitor candidate that is designed to allow for controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint antibody therapies Forward-looking statements in this press release include statements about: the potential to lead to a functional cure for HBV; the result of Arbutus’ review of its pipeline and development plans for its cHBV programs; the potential for Arbutus’ product candidates to achieve success in clinical trials; Arbutus’ plans with respect to the ongoing patent litigation matters and the expected timing thereof; the potential that the management changes will renew focus on advancing the Company’s pipeline efficiently and delivering value to patients and Arbutus’ stakeholders; the expectation that 2025 will be a transformative year for Arbutus; and Arbutus’ expected financial condition or investor perceptions; and risks related to the sufficiency of Arbutus’ cash resources for its foreseeable and unforeseeable operating expenses and capital expenditures 2025 at 6:42 pm ET.css-79elbk{position:relative;}The Baltimore County Police Department said it fatally shot a man armed with a bow and arrow Wednesday in Arbutus (Jacob Baumgart/Patch Stock Photo)Last updated Wednesday at 6:42 p.m MD — Police said they fatally shot a man armed with a bow and arrow Wednesday in Arbutus sparking brief lockouts at three nearby schools Officers said they were called to the 5100 block of Leeds Avenue around 10:25 a.m Authorities said police in uniform and plain clothes engaged the armed man "During this encounter, officers responded to the actions of the armed subject, resulting in one detective discharging his firearm striking the adult male," the Baltimore County Police Department said in a press release Officers said they immediately administered life-saving measures Authorities said the man was taken to a nearby hospital Police announced at 10:47 a.m. on X that "residents can expect a police presence in the area" of Leeds Avenue and Greystone Road Arbutus Middle School and Maiden Choice School were put on lockout status after "our Safety Manager made us aware of an individual in the community who was shooting a crossbow." The lockout was lifted at 10:38 a.m Maryland Attorney General Anthony Brown at 1:24 p.m. confirmed the fatality Brown's office is legally required to investigate all deadly encounters with police "I want you to be assured that the safety of our students is our top priority please do not hesitate to contact the school," Maile said 2025 (GLOBE NEWSWIRE) -- Genevant Sciences a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences and Arbutus Biopharma Corporation (Nasdaq: ABUS) today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna the enforcement actions target alleged infringing activities in 30 countries Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and additional Moderna products that Moderna has represented use the same LNP technology Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the U.S and Europe indicating that the samples contain LNPs falling under the protective scope of the claims of their lipid composition patents The UPC actions together seek relief for: Austria Today’s actions expand on Arbutus and Genevant’s ongoing enforcement proceeding in the U.S District Court for the District of Delaware seeking fair compensation for Moderna’s alleged infringement of six U.S patents in the manufacture and sale of Spikevax® A jury trial is currently scheduled for September 2025 It is well established in the scientific literature that the most significant technological hurdle to developing and deploying medicines using mRNA is engineering a safe and effective way to deliver the mRNA to human cells Scientists at Arbutus and Genevant have spent years developing and refining LNP delivery technology which has been licensed for various applications to many different third parties Arbutus and Genevant’s LNP technology relies on microscopic particles built from four carefully selected types of fat-like molecules to shelter and protect mRNA molecules and to enable them to travel through the human body to a target cell and through the target cell’s membrane before releasing the mRNA mRNA would quickly degrade in the body and be ineffective Forward-looking statements in this press release include statements about: Arbutus’ plans with respect to the ongoing patent litigation matters Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results Left to cherish her memory are her parents Roger Cannady and Daisy Arbutus Cannady of Vander her beloved husband Joseph Link of the home (Kaitlynn) of Lumberton and Jeremiah Link (Morgan) of Bladenboro Loretta Ketterman (Jack) of Vander and one grandson  Daisy was a devoted and loving daughter She enjoyed spending time with them whether it was fishing trips to the beach or mountains or sitting down to a meal together Daisy loved nothing better than spoiling her grandson Jacob and baking goodies for the family Her unconditional love is the legacy that will forever hold their hearts A 16-year-old boy was fatally shot in a residential neighborhood in Arbutus on Sunday afternoon Officers were dispatched to the 4000 block of Alan Drive off Wilkens Avenue for reports of shots fired around 2:10 p.m they found a teenage victim who had sustained at least one gunshot wound The victim was later pronounced dead on the scene They request anyone with information about the case to contact 410-887-4636 (INFO) Sapna Bansil sapna.bansil@thebaltimorebanner.com Sapna Bansil is a regional reporter and Roy W She graduated in May 2024 with her master's from the University of Maryland and held internships at The Philadelphia Inquirer and The Washington Post 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) today announced changes to its board of directors and the appointment of Lindsay Androski Androski will also serve as a member of the Company’s board of directors Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology She has served in a variety of roles at Roivant She is currently special counsel at Genevant with responsibilities including LNP litigation “I would like to thank Michael McElhaugh and the rest of the board for their service,” said Lindsay Androski I am excited to lead the company into its next chapter We believe these changes in leadership will enable renewed focus on advancing the company’s pipeline efficiently and maximizing the company’s contributions to LNP delivery technology through Genevant both of which we expect will deliver greater value to shareholders and patients alike.” four new directors have joined the board: Robert Alan Beardsley In connection with the appointment of these new directors all members of the existing board of directors have stepped down effective immediately and the board was reduced to five members in total The Company is considering additional directors with expertise in clinical development and may expand the board in the coming months The Company will temporarily pause participation in investor meetings and conferences while the new board and management team reviews development plans and strategic options for its hepatitis B programs statements about Arbutus’s consideration of additional directors for its board Genevant Sciences and Arbutus Biopharma (ABUS) have initiated five international patent infringement lawsuits against Moderna across 30 countries The legal actions target Moderna's alleged unauthorized use of their lipid nanoparticle (LNP) technology in Spikevax® and mRESVIA® products The lawsuits have been filed in multiple jurisdictions including Canada The companies are seeking monetary damages and injunctions against Moderna's products Evidence from testing commercial Moderna samples from the U.S and Europe indicates the presence of LNPs that fall under their patent claims This international enforcement expands on their ongoing U.S where a jury trial is scheduled for September 2025 was developed by Arbutus and Genevant scientists and has been licensed to various third parties Genevant Sciences e Arbutus Biopharma (ABUS) hanno avviato cinque cause legali internazionali per violazione di brevetto contro Moderna in 30 paesi Le azioni legali mirano all'uso presunto non autorizzato della loro tecnologia dei nanoparticelle lipidiche (LNP) nei prodotti Spikevax® e mRESVIA® Le cause sono state depositate in diverse giurisdizioni Svizzera e il Tribunale Unificato dei Brevetti (UPC) Le aziende stanno cercando risarcimenti monetari e ingiunzioni contro i prodotti di Moderna Le prove ottenute testando campioni commerciali di Moderna provenienti da Stati Uniti ed Europa indicano la presenza di LNP che rientrano nelle loro rivendicazioni di brevetto Questa enforcement internazionale si aggiunge al procedimento in corso negli Stati Uniti in Delaware dove è previsto un processo con giuria per settembre 2025 importante per la somministrazione di medicinali mRNA è stata sviluppata da scienziati di Arbutus e Genevant ed è stata concessa in licenza a vari terzi Genevant Sciences y Arbutus Biopharma (ABUS) han iniciado cinco demandas internacionales por infracción de patentes contra Moderna en 30 países Las acciones legales se dirigen al supuesto uso no autorizado de su tecnología de nanopartículas lipídicas (LNP) en los productos Spikevax® y mRESVIA® Las demandas se han presentado en múltiples jurisdicciones Suiza y el Tribunal de Patentes Unificado (UPC) Las empresas buscan daños monetarios e interdictos contra los productos de Moderna La evidencia de pruebas de muestras comerciales de Moderna de EE y Europa indica la presencia de LNP que se encuentran bajo sus reclamaciones de patente Esta aplicación internacional se suma al procedimiento en curso en EE donde se programó un juicio con jurado para septiembre de 2025 importante para la entrega de medicamentos de ARNm fue desarrollada por científicos de Arbutus y Genevant y ha sido licenciada a varios terceros Genevant Sciences와 Arbutus Biopharma (ABUS)는 Moderna에 대해 30개국에서 다섯 건의 국제 특허 침해 소송을 시작했습니다 이 법적 조치는 Spikevax® 및 mRESVIA® 제품에서 그들의 지질 나노입자(LNP) 기술의 무단 사용을 겨냥하고 있습니다 이들 회사는 Moderna의 제품에 대한 금전적 손해배상과 금지 명령을 요청하고 있습니다 mRNA 의약품 전달에 중요한 LNP 기술은 Arbutus와 Genevant 과학자들에 의해 개발되었으며 여러 제3자에게 라이선스가 부여되었습니다 Genevant Sciences et Arbutus Biopharma (ABUS) ont engagé cinq poursuites internationales pour violation de brevet contre Moderna dans 30 pays Les actions en justice visent l'utilisation présumée non autorisée de leur technologie des nanoparticules lipidiques (LNP) dans les produits Spikevax® et mRESVIA® Les poursuites ont été déposées dans plusieurs juridictions la Suisse et le Tribunal Unifié des Brevets (UPC) Les entreprises demandent des dommages-intérêts et des injonctions contre les produits de Moderna Des preuves provenant de tests d'échantillons commerciaux de Moderna des États-Unis et d'Europe indiquent la présence de LNP qui relèvent de leurs revendications de brevet Cette application internationale s'ajoute à la procédure en cours aux États-Unis dans le Delaware où un procès avec jury est prévu pour septembre 2025 importante pour la délivrance de médicaments à ARNm a été développée par des scientifiques d'Arbutus et de Genevant et a été concédée sous licence à divers tiers Genevant Sciences und Arbutus Biopharma (ABUS) haben fünf internationale Klagen wegen Patentverletzung gegen Moderna in 30 Ländern eingereicht Die rechtlichen Schritte zielen auf die angebliche unbefugte Nutzung ihrer Lipid-Nanopartikel (LNP)-Technologie in den Produkten Spikevax® und mRESVIA® ab Die Klagen wurden in mehreren Jurisdiktionen eingereicht die Schweiz und das Einheitliche Patentgericht (UPC) Die Unternehmen fordern finanzielle Entschädigungen und Unterlassungsverfügungen gegen die Produkte von Moderna Beweise aus Tests kommerzieller Moderna-Proben aus den USA und Europa zeigen das Vorhandensein von LNPs Diese internationale Durchsetzung erweitert das laufende Verfahren in den USA in Delaware wo ein Geschworenenprozess für September 2025 angesetzt ist die für die Lieferung von mRNA-Medikamenten wichtig ist wurde von Wissenschaftlern von Arbutus und Genevant entwickelt und an verschiedene Dritte lizenziert This expanded patent litigation represents a significant escalation in Arbutus and Genevant's enforcement strategy By filing in multiple strategic jurisdictions—Canada and the Unified Patent Court covering 27 European countries—they've created a comprehensive legal net targeting 30 countries simultaneously The litigation focuses on lipid nanoparticle (LNP) technology the critical delivery system that enables mRNA therapeutics to function by protecting the mRNA and facilitating cellular uptake What strengthens their position is the submission of physical evidence from testing commercial Moderna samples suggesting they've conducted due diligence before filing The request for both monetary damages and injunctive relief is particularly aggressive the threat of injunctions creates substantial leverage as it could potentially force Moderna's products off market in multiple territories The UPC filings are especially significant as they streamline enforcement across numerous European markets simultaneously This multi-jurisdictional approach accomplishes several strategic objectives: it increases settlement pressure and creates the possibility for favorable rulings in some jurisdictions to influence others these international filings create additional pressure points that could accelerate settlement discussions rather than risk adverse rulings across multiple markets This expanded patent enforcement campaign significantly enhances Arbutus's potential for substantial financial recovery and strengthens its position in the LNP technology marketplace The litigation targets not just Spikevax but potentially other Moderna products using similar LNP technology this aggressive patent strategy highlights that Arbutus's intellectual property portfolio may be undervalued relative to its fundamental importance in enabling mRNA therapeutics The company appears confident in the strength of its patents evidenced by the investment in simultaneous multi-jurisdictional litigation The financial implications extend beyond potential damages from Moderna A successful outcome would validate Arbutus's patent portfolio potentially increasing licensing revenue from other pharmaceutical companies developing mRNA therapies This could transform Arbutus from being valued primarily on its clinical pipeline to recognition as a key technology enabler in the mRNA space this litigation introduces both opportunity and risk and litigation outcomes are inherently unpredictable the comprehensive approach suggests a strong conviction in their legal position The most significant near-term catalyst will be the U.S though developments in any of these international cases could trigger settlement discussions sooner Already have an account? Login Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection today announced its 2025 corporate objectives and provided a financial update “We enter 2025 with solid financial footing and strong momentum in achieving our mission of developing a functional cure for cHBV a disease that affects more than 250 million people worldwide and is a leading cause of liver cancer,” said Michael J Interim President and Chief Executive Officer of Arbutus “The data we reported late last year from our IM-PROVE I Phase 2a clinical trial showed a meaningful functional cure rate and immune activation in cHBV patients that were treated with our RNAi therapeutic interferon and nucleos(t)ide analogue (NA) therapy These data support our belief that imdusiran is differentiated from other RNAi therapeutics in development for HBV we plan to initiate a Phase 2b clinical trial combining imdusiran interferon and NA therapy in the first half of 2025.”      the Company is planning to initiate a Phase 2b clinical trial of imdusiran combined with IFN and NA therapy AB-101 is our oral PD-L1 inhibitor candidate that we believe will allow for controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint antibody therapies when used in combination with other approved and investigational agents could potentially lead to a functional cure in patients chronically infected with HBV Forward-looking statements in this press release include statements about: the potential to lead to a functional cure for HBV; Arbutus’ future development plans for its product candidates; the expected timing cost and results of Arbutus’ clinical development plans and clinical trials with respect to its product candidates; Arbutus’ expectations with respect to the cost initiation and the release of data from its clinical trials and the expected timing thereof; the potential for Arbutus’ product candidates to achieve success in clinical trials; Arbutus’ expectations with respect to utilizing its ATM program; Arbutus’ plans with respect to the ongoing patent litigation matters; and Arbutus’ expected financial condition including the anticipated duration of its cash runway its expectations regarding its 2025 cash burn and the timing and need for additional capital or investor perceptions; and risks related to the sufficiency of Arbutus’ cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures Lisa M. CaperelliVice President, Investor Relations  Phone: 215-206-1822  Email: lcaperelli@arbutusbio.com We’re fighting for improved benefits and fair wages that keep pace with the cost of living Ninety-five per cent of union employees at the Arbutus Club earn less than the Living Wage—the salary required in Vancouver for two working parents to meet the basic needs of a family of four Unifor members vote for strike action if necessary at Arbutus Club Arbutus Biopharma (Nasdaq: ABUS) announced significant leadership changes appointing Lindsay Androski as Chief Executive Officer replacing Interim President and CEO Michael J an MIT-trained biologist with nearly 30 years of experience in biotechnology will also join the company's board of directors The clinical-stage biopharmaceutical company has also appointed four new directors to its board: Robert Alan Beardsley All previous board members have stepped down The company may consider adding directors with clinical development expertise in the coming months Androski stated that these leadership changes aim to enable "renewed focus on advancing the company's pipeline efficiently and maximizing the company's contributions to LNP delivery technology through Genevant." The company will temporarily pause investor meetings while the new leadership reviews development plans and strategic options for its hepatitis B programs Arbutus Biopharma (Nasdaq: ABUS) ha annunciato significative modifiche nella leadership nominando Lindsay Androski come Amministratore Delegato che sostituisce il Presidente e CEO ad interim Michael J biologa formata al MIT con quasi 30 anni di esperienza nei settori della biotecnologia entrerà anche a far parte del consiglio di amministrazione dell'azienda La società biofarmaceutica in fase clinica ha anche nominato quattro nuovi membri nel suo consiglio: Robert Alan Beardsley Tutti i membri precedenti del consiglio si sono dimessi riducendo il consiglio a un totale di cinque membri L'azienda potrebbe considerare di aggiungere direttori con esperienza nello sviluppo clinico nei prossimi mesi Androski ha dichiarato che queste modifiche nella leadership mirano a consentire un "rinnovato focus sull'avanzamento del pipeline dell'azienda in modo efficiente e a massimizzare i contributi dell'azienda alla tecnologia di somministrazione LNP attraverso Genevant." L'azienda sospenderà temporaneamente gli incontri con gli investitori mentre la nuova leadership rivede i piani di sviluppo e le opzioni strategiche per i suoi programmi contro l'epatite B Arbutus Biopharma (Nasdaq: ABUS) anunció cambios significativos en su liderazgo nombrando a Lindsay Androski como Directora Ejecutiva reemplazando al Presidente y CEO interino Michael J bióloga formada en el MIT con casi 30 años de experiencia en biotecnología también se unirá a la junta directiva de la empresa La compañía biofarmacéutica en etapa clínica también ha nombrado a cuatro nuevos directores en su junta: Robert Alan Beardsley Todos los miembros anteriores de la junta han renunciado reduciendo la junta a un total de cinco miembros La empresa podría considerar la adición de directores con experiencia en desarrollo clínico en los próximos meses Androski declaró que estos cambios en el liderazgo tienen como objetivo permitir un "nuevo enfoque en avanzar la cartera de la empresa de manera eficiente y maximizar las contribuciones de la empresa a la tecnología de entrega de LNP a través de Genevant." La empresa pausará temporalmente las reuniones con inversores mientras el nuevo liderazgo revisa los planes de desarrollo y las opciones estratégicas para sus programas de hepatitis B Arbutus Biopharma (Nasdaq: ABUS)는 주요 리더십 변화를 발표하며 Lindsay Androski를 CEO로 임명하고 임상 단계의 생물 의약품 회사는 이사회에 네 명의 새로운 이사를 추가로 임명했습니다: Robert Alan Beardsley 회사는 향후 몇 달 내에 임상 개발 전문성을 가진 이사를 추가하는 것을 고려할 수 있습니다 Androski는 이러한 리더십 변화가 "회사의 파이프라인을 효율적으로 발전시키고 Genevant를 통한 LNP 전달 기술에 대한 회사의 기여를 극대화하는 데 새롭게 집중할 수 있도록" 하기 위한 것이라고 밝혔습니다 회사는 새로운 리더십이 B형 간염 프로그램에 대한 개발 계획과 전략적 옵션을 검토하는 동안 투자자 회의를 일시적으로 중단할 것입니다 Arbutus Biopharma (Nasdaq: ABUS) a annoncé des changements significatifs dans sa direction nommant Lindsay Androski au poste de Directrice Générale remplaçant le Président et CEO par intérim Michael J biologiste formée au MIT avec près de 30 ans d'expérience en biotechnologie rejoindra également le conseil d'administration de l'entreprise L'entreprise bio-pharmaceutique en phase clinique a également nommé quatre nouveaux administrateurs à son conseil : Robert Alan Beardsley Tous les membres précédents du conseil ont démissionné réduisant le conseil à un total de cinq membres L'entreprise pourrait envisager d'ajouter des administrateurs ayant une expertise en développement clinique dans les mois à venir Androski a déclaré que ces changements de leadership visent à permettre un "nouveau focus sur l'avancement efficace du pipeline de l'entreprise et à maximiser les contributions de l'entreprise à la technologie de livraison LNP à travers Genevant." L'entreprise suspendra temporairement les réunions avec les investisseurs pendant que la nouvelle direction examine les plans de développement et les options stratégiques pour ses programmes de lutte contre l'hépatite B Arbutus Biopharma (Nasdaq: ABUS) hat bedeutende Veränderungen in der Unternehmensführung angekündigt und Lindsay Androski zur Geschäftsführerin ernannt die den interimistischen Präsidenten und CEO Michael J eine am MIT ausgebildete Biologin mit fast 30 Jahren Erfahrung in Biotechnologie wird auch dem Vorstand des Unternehmens beitreten Das biopharmazeutische Unternehmen in der klinischen Phase hat außerdem vier neue Direktoren in seinen Vorstand berufen: Robert Alan Beardsley Alle vorherigen Vorstandsmitglieder haben ihren Rücktritt erklärt wodurch der Vorstand auf insgesamt fünf Mitglieder reduziert wurde Das Unternehmen könnte in den kommenden Monaten die Hinzufügung von Direktoren mit Fachwissen in der klinischen Entwicklung in Betracht ziehen dass diese Veränderungen in der Führung darauf abzielen einen "neuen Fokus auf die effiziente Weiterentwicklung der Unternehmenspipeline und die Maximierung der Beiträge des Unternehmens zur LNP-Abliefertechnologie durch Genevant" zu ermöglichen Das Unternehmen wird vorübergehend die Investorenmeetings aussetzen während die neue Führung die Entwicklungspläne und strategischen Optionen für die Programme zur Bekämpfung von Hepatitis B überprüft has died in a one-alarm apartment fire in Arbutus according to the Baltimore County Fire Department the fire crew responded to a report of an apartment fire at the 4400 block of Alan Drive Authorities reported that another rescue crew was dispatched after the resident told the 911 operator that he could not escape ALSO READ| Amazon vehicle stolen in Northeast Baltimore, eventually recovered the fire crew learned the fire was coming from the second floor of the apartment Investigators ruled the fire to be accidental from unattended cooking 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Data to be presented in late-breaker poster session at AASLD – The Liver Meeting® on Monday 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) today announced new data from its IM-PROVE I Phase 2a clinical trial (AB-729-201) showing that six doses of imdusiran and 24 weeks of pegylated interferon alfa-2α (IFN) added to ongoing nucleos(t)ide analogue (NA) therapy led to a functional cure rate of 50% (3/6) in HBeAg-negative patients with baseline HBsAg levels less than 1000 IU/mL and an overall functional cure rate of 25% (3/12) Patients with HBsAg levels less than 1000 IU/mL represent a significant portion of the cHBV population These data will be presented as a late-breaker poster presentation on November 18 2024 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024 we are seeing a meaningful percentage of HBV patients functionally cured with an RNAi therapeutic and interferon,” commented Professor Man-Fung Yuen Chief of the Division of Gastroenterology and Hepatology the University of Hong Kong and Principal Investigator of the IM-PROVE I clinical trial “While 48 weeks of interferon can be used as a standard of care treatment for HBV patients historically less than 10% of patients experience a functional cure with the combination of imdusiran and 24 weeks of interferon we see a 50% functional cure rate in HBV patients with HBsAg less than 1000 IU/mL at baseline and a 25% functional cure rate overall I was pleased to see that this regimen with a short course of interferon was generally safe and well-tolerated These data are extremely impressive and provide hope for the millions of HBV patients worldwide and the medical community that a finite curative treatment is possible with imdusiran and interferon.” Key data from patients in Cohort A1 that received 6 doses of imdusiran plus 24 weeks of IFN in addition to ongoing NA therapy include: “IM-PROVE I: Imdusiran in Combination with Short Courses of Pegylated Interferon Alfa-2a in Virally Suppressed HBeAg Negative Subjects with Chronic HBV (cHBV) Infection Leads to Functional Cure” is available on the Company’s website and provides the complete data set for all four cohorts of patients dosed in this clinical trial Additional immune activation data in those patients in Cohort A1 that achieved a functional cure will be presented by Dr Immunobiology and Biomarkers Research at Arbutus Biopharma in a poster titled “Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon Alfa Reveals Phases of Immune Activation.” The data in this poster show that patients in Cohort A1 had greater increases in favorable immune biomarkers than those in other cohorts Functionally cured patients and those with baseline HBsAg <1000 IU/mL had elevations of key immune biomarkers during the imdusiran lead-in suggesting immune activation induced by imdusiran plus IFN treatment “We are extremely excited to have functionally cured these patients with the imdusiran and interferon treatment regimen There is a significant need for a functional cure for the more than 250 million patients chronically infected with HBV worldwide,” commented Dr Chief Medical Officer of Arbutus Biopharma “Excess production of surface antigen is believed to contribute to host immune exhaustion resulting in inadequate immune response and failure to suppress the virus These data support our belief that lowering surface antigen with imdusiran and incorporating an immunomodulator in the treatment regimen provides a functional cure in some patients with cHBV We thank all the patients and investigators who participated in this clinical trial.” All of the above posters that will be presented at AASLD – The Liver Meeting can be accessed through the Arbutus website under Publications The IM-PROVE I Phase 2a Clinical trial (AB-729-201; NCT04980482) enrolled 43 HBeAg-negative NA-suppressed patients with cHBV infection After a 24-week lead-in with imdusiran (60 mg every 8 weeks patients were randomized into one of the following four cohorts: Cohort A1: imdusiran (2 doses) + NA + IFN weekly for 24 weeks (n=12) Cohort A2: NA + IFN weekly for 24 weeks (n=13) Cohort B1: Imdusiran (1 dose) + NA + IFN weekly for 12 weeks (n=8) and Cohort B2: NA + IFN weekly for 12 weeks (n=10) After completion of the IFN treatment period (Week 52 for cohorts A1 and A2 and Week 40 for cohorts B1 and B2) patients underwent a 24-week follow-up period on NA therapy alone and were then assessed for discontinuation of NA therapy Patients with ALT levels less than two times the upper limit of normal and HBsAg <100 IU/mL at two consecutive visits at least 24 weeks after the last dose of imdusiran qualified to discontinue all therapy and will be followed for at least 48 weeks Imdusiran is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens including hepatitis B surface antigen imdusiran achieved meaningful functional cure rates in patients with cHBV when combined with pegylated interferon alfa-2α and nucleos(t)ide analogue therapy Additional clinical data generated thus far has shown imdusiran to be generally safe and well-tolerated Plans are underway to advance imdusiran into a Phase 2b clinical trial Forward-Looking Statements and Information Forward-looking statements in this press release include statements about: the IM-PROVE I Phase 2a clinical trial data; the potential for finite curative treatment to be possible with imdusiran among other things: the effectiveness and timeliness of preclinical studies and clinical trials among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; market shifts may require a change in strategic focus Lisa M. Caperelli  Vice President, Investor Relations  Phone: 215-206-1822  Email: lcaperelli@arbutusbio.com serious injury crash this weekend on Interstate 95 in Baltimore County Troopers said the wreck happened Sunday around 2:50 a.m A 2008 Mercury Mountaineer SUV hit the back of a 2004 tractor-trailer Police said a 2016 Toyota Corolla sedan then hit the Mercury The Mercury and Toyota drivers were both taken to the University of Maryland R Adams Cowley Shock Trauma Center in Baltimore The Maryland State Police is still investigating Charges are pending the outcome of the investigation and a consultation with the Office of the State's Attorney in Baltimore County This map shows the area where authorities said the crash happened HBV therapies developer Arbutus Biopharma Corp. (NASDAQ:ABUS) has named Lindsay Androski CEO and replaced its entire board Androski is special counsel at Genevant Sciences Corp. an RNA therapeutics company set up by Arbutus and Roivant Sciences Ltd (NASDAQ:ROIV) in 2018 to advance treatments using Arbutus’ liquid nanoparticle and ligand conjugation technologies who had been Arbutus’ interim president and CEO since the start of 2024 has resigned from the board along with Daniel Burgess Arbutus said the new team will review its development plans and strategic options for its HBV programs while “maximizing the company's contributions to LNP delivery technology through Genevant.”.. Arbutus Biopharma Corp. Crescent Biopharma Inc. Ottimo Pharma Ltd. Repare Therapeutics Inc. Senti Biosciences Inc. Health Care Heroes Arbutus Shopping Center changes hands with $16.65M sale at 1052-1082 Maiden Choice Lane and 4733-4741 and 4738 Westland Blvd. spans two separate parcels totaling 7.88 acres It is home to a tenant mix of national brands such as Walgreens in addition to various local service-oriented businesses broke ground on a 30-acre mixed-use business community in Wake Forest[...] Ryan Furniture in Havre de Grace will close mid-May after 76 years The family is selling the longtime Route 4[...] Baltimore residents are suing over tax sales The Baltimore Ravens say they are releasing kicker Justin Tucker months after reports that he was accused of [...] Bankruptcy Judge Michelle Harner's order seeks to preserve victims’ rights under the Child Victims Act [...] The Walters Art Museum is not subject to the Maryland Public Information Act Sign up for your daily digest of Maryland news Supporting small businesses is an investment in Maryland’s prosperity – one that drives growth a[...] Listen to this article As I write this shortly after Earth Day 2025 I have on my desk a 46-page pub[...] Listen to this article Based on recent data provided by the U.S there was [...] I took the oath prescribed in Maryland Business Occupations[...] Listen to this article Maryland has a lot to celebrate when it comes to climate action but also muc[...] Lawmakers in Annapolis have passed hastily considered extended [...] Listen to this article In the past decade employers who sponsor pension plans have been subject to [...] Submit an entry for the business calendar The Daily Record is a digital-first daily news media company focused on law Get our free e-alerts & breaking news notifications Subscribe for access to the latest digital and special editions Click here for information about plaques permissions and reprints of previous editions Javascript is disabled in your web browser You can't access site without javascript so please enable it for your seamless and unintruppted user experience of our website We have the address for the funeral home & the family on file If you're not happy with your card we'll send a replacement or refund your money On January 27, 2022, Betty Arbutus (Arby) Harmon Brannon died peacefully in her home, surrounded by her four children. She was 93 years old. She was born on September 9, 1928, in Bessemer City, North Carolina, to the late Russell and Irene Harmon.... View Obituary & Service Information The family of Betty Arbutus (Arby) Brannon created this Life Tributes page to make it easy to share your memories © 2025 Cavin-Cook Funeral Home & Crematory Made with love by funeralOne Metrics details The demand for nontimber forest products (NTFPs) has increased significantly in recent years Hundreds of plant species that grow naturally in Türkiye have medicinal and aromatic value Medicinal and aromatic plants are primarily used as a sources of tea are used for decorative purposes and as fuel wood in many wood-based industries they also have a wide range of uses in packaging the fruits of these trees are widely consumed by humans and animals because they are rich in sugar and vitamin C It is predicted that changes in climatic conditions will significantly change the distribution composition and function of forests threatening biodiversity The purpose of this study was to model current and future potential geographical distributions of Arbutus unedo L. which is among the species that naturally grow in Türkiye and is of substantial value in terms of its ecological contribution to forest ecosystems based on species presence data and environmental variables (bioclimatic variables and altitude) The current and future distribution area models for Arbutus unedo L indicate that the potential distribution areas of the species in the coming years will gradually decrease which represents the highest level of world resource usage this gradual decrease will reach its highest level and there will be no suitable distribution area left for the species it is predicted that the species will become endangered In-situ and ex-situ conservation measures need to be taken to ensure the sustainability of the species in forestry and landscape areas The SSPs created for the models are based on five narratives that describe broad socioeconomic trends that may shape future societies predicting how socioeconomic conditions will affect the implementation of climate policy represents a moderate level of mitigation and adaptation and SSP5 represents a high level of use of fuel and world resources The algorithm takes the projection of the sample points on climatic variables yields the attribute information of the species in those areas and determines points suitable for the species based on the determined attributes by randomly assigning points in the background Areas that have similar attributes in the obtained and future projection data are considered suitable distribution areas for the species 10000 background points were used according to the area size The variables used in the newly created model were BIO 2 Two different models were constructed for two shared socioeconomic pathways (SSP2-4.5 and SSP5-8.5) under greenhouse warming scenarios All variable rasters were at a 30 arc-second resolution Five classifications were made for maps of potential distribution areas (0 is not suitable 0.50–0.75 is suitable and 0.75–1.0 is very suitable) the maps obtained as raster were converted into vector format and the areal coverage is presented in tables Predictive accuracy of the model variables the Jackknife test Potential distribution of Arbutus unedo—created using QGIS v3.2435. The existing data and the model created for the current study were consistent The distribution area of Arbutus unedo is on the coast of the country and its current distribution is far northwards on the northern coast of Marmara sea in the models created for the distribution areas for the years 2041–2060 and 2081–2100 unedo will start to withdraw from the Mediterranean and Aegean regions where it already has a limited distribution and its distribution will shift to the northern parts of the Marmara region the presence of very suitable distribution areas for the species in the northern areas will be severely restricted which has a wide distribution in our country with MaxEnt; the model output suggested that the species distribution areas will shrink in the future Since the ethnobotanical and food use of this species is widespread in Türkiye and as long as this level of use of the Earth’s resources continues extinction will be inevitable for the Strawberry tree and many other species Climate change is important from a wide variety of perspectives from the distribution of plant species to their protection and use The MaxEnt model predicted significant fluctuations in A unedo distribution areas in Türkiye over the next 50 years unedo are not significantly affected in the SSP2-4.5 projection from climate change there is a significant decrease in the distribution area of this species in the SSP5-8.5 projection this study conducted at the geographical boundaries of Türkiye showed that the distribution of Strawberry trees in the coming years will gradually decrease and the species will become more threatened will not be maintained in the Aegean strip in the future and will decrease by shifting to the northern latitudes in the western Black Sea and Marmara regions will shift its distribution to northern latitudes not only in Türkiye but also in other Mediterranean countries To avoid economic and ecological losses related to Strawberry trees it is important to conduct studies on a global scale rather than on local scales to ensure the future of Strawberry trees No new data were created or analysed in this study Data sharing is not applicable to this article The data presented in this study are available upon request from the corresponding author Uzun, A. & Sarikaya, A. G. Estimation of current and future potential distribution areas of Pistacia terebinthus L. by random forest regression algorithm. Artvin Coruh Univ. J. For. Fac. 24(2), 160–169. https://doi.org/10.17474/artvinofd.1298275 (2023) Abdelaal, M., Fois, M., Fenu, G. & Bacchetta, G. Using MaxEnt modeling to predict the potential distribution of the endemic plant Rosa arabica crép in Egypt. Ecol. Inform. 50, 68–75. https://doi.org/10.1016/j.ecoinf.2019.01.003 (2019) Distribution of rose hip (Rosa canina L.) under current and future climate conditions Li, G., Huang, J., Guo, H. & Du, S. Projecting species loss and turnover under climate change for 111 Chinese tree species. For. Ecol. Manage. 477, 118488. https://doi.org/10.1016/j.foreco.2020.118488 (2020) Chakraborty, A., Joshi, P. K. & Sachdeva, K. Predicting distribution of major forest tree species to potential impacts of climate change in the central Himalayan region. Ecol. Eng. 97, 593–609. https://doi.org/10.1016/j.ecoleng.2016.10.006 (2016) Zhao, H., Zhang, H. & Xu, C. Study on Taiwania cryptomerioides under climate change: MaxEnt modeling for predicting the potential geographical distribution. Glob. Ecol. Conserv. 24, e01313. https://doi.org/10.1016/j.gecco.2020.e01313 (2020) Dyderski, M. K., Paź, S., Frelich, L. E. & Jagodziński, A. M. How much does climate change threaten European forest tree species distributions?. Glob. Change Biol. 24, 1150–1163. https://doi.org/10.1111/gcb.13925 (2018) Zhang, K., Yao, L., Meng, J. & Tao, J. Maxent modeling for predicting the potential geographical distribution of two peony species under climate change. Sci. Total Environ. 634, 1326–1334. https://doi.org/10.1016/j.scitotenv.2018.04.112 (2018) Rana, S. K., Rana, H. K., Luo, D. & Sun, H. Estimating climate-induced ‘nowhere to go’ range shifts of the Himalayan incar-villea juss. Using multi-model median ensemble species distribution models. Ecol. Ind. https://doi.org/10.1016/j.ecolind.2020.107127 (2020) Yi, Y. J., Cheng, X., Yang, Z. F. & Zhang, S. H. Maxent modeling for predicting the potential distribution of endangered me-dicinal plant (H. riparia Lour) in Yunnan, China. Ecol. Eng. 92, 260–269. https://doi.org/10.1016/j.ecoleng.2016.04.010 (2016) Akhter, S. et al. Habitat distribution modelling to identify areas of high conservation value under climate change for Mangifera sylvatica Roxb. of Bangladesh. Land Use Policy 60, 223–232. https://doi.org/10.1016/j.landusepol.2016.10.027 (2017) Predictive habitat distribution models in ecology Assessment of impact of climate change on rhododendrons in Sikkim Himalayas using maxent modelling: Limitations and challenges Predicting the potential distribution of Crataegus azarolus L under climate change in central zagros Iran Parmesan, C. & Hanley, M. E. Plants and climate change: Complexities and surprises. Ann. Bot. 116, 849–864. https://doi.org/10.1093/aob/mcv169 (2015) Modeling of present and future potential distribution areas of Thymus praecox opiz in Turkey according to the maxent algorithm Arslan, E. S. et al. Modeling of the current and future potential distribution of stinking juniper (juniperus foetidissima Willd) with machine learning techniques. Eur. J. Sci. Technol. 22, 1–12. https://doi.org/10.31590/ejosat.848961 (2021) A statistical explanation of MaxEnt for ecologists Very high resolution interpolated climate surfaces for global land areas Global climate and weather data, WorldClim, https://worldclim.org/data/index.html (2020) KTÜ Orman Fakültesi Trabzon Turkiye 167 (1993) Development of the MIROC-ES2L earth system model and the evaluation of biogeochemical processes and feedbacks Investigations on Some Morphological Feautures of Arbutus andrachne L distributed in Çandır (Sütçüler-Isparta) Province Sanlidere Aloglu, H., Gokgoz, Y. & Bayraktar, M. Strawberry tree fruits (Arbutus unedo L.) ice cream production, investi-gation of physical, chemical and sensorial parameters. J. Food 43, 1030–1039. https://doi.org/10.15237/gida.GD18098 (2018) GBIF.org. Available online: GBIF Occurrence Download https://doi.org/10.15468/dl.asgec4 (25 October 2023) Pomological characteristics of strawberry tree (Arbutus unedo L.) grown in Marmara island Flora of Turkey and the East Aegean Islands Vol lnvestigation of morphological and pomological characteristics of Strawberry tree (Arbutus unedo L.) population in the natural flora of Çanakkale district TUBIVES. Avaliable online: Turkish Plants Data Service http://194.27.225.161/yasin/tubives/index.php?sayfa=1&tax_id=9301 (16 June 2023) The leaf traits of a Mediterranian species (Arbutus unedo L.) in an undisturbed and planted forests in Euxine region QGIS. QGIS 3.24 Tisler—A Free and Open GIS. https://www.qgis.org/en/site/forusers/visualchangelog322/index.html (13 June 2023) Predicting species distributions from small numbers of occurrence records: A test case using cryptic geckos in madagascar Estimating optimal complexity for ecological niche models: A jackknife approach for species with small sample sizes Uzun, A. & Orucu, O. K. Prediction of present and future spread of Adenocarpus complicatus (L.) Gay species according to climate variables. Turk. J. For. 21, 4. https://doi.org/10.18182/2Ftjf.779776 (2020) Phillips, S. J. & Dudik, M. Modeling of species distributions with Maxent: New extensions and a comprehensive evaluation. Ecography 31(2), 161–175. https://doi.org/10.1111/j.0906-7590.2008.5203.x (2008) The potential geographic distribution of Radopholus similis in China POC plots: Calibrating species distribution models with presence-only data Potential distribution range of invasive plant species in Spain Prediction of future and current distribution of phoenix theophrasti Gr with using MaxEnt model and its utilizition for planting design Maximum entropy modeling of species geographic distributions Maxent modeling for predicting the potantial distribution of Arbutus andrachne L Effects of climate change on main forest tree species in Turkey Predicting of the current and future geographical distribution of Laurus nobilis L Akyol, A. & Orucu, O. K. Investigation and evaluation of stone pine (Pinus pinea L.) current and future potential distribution under climate change in Turkey. Cerne 25(4), 15–423. https://doi.org/10.1590/01047760201925042643 (2019) Al-Qaddi, N., Vessella, F., Stephan, J., Al-Eisawi, D. & Schirone, B. Current and future suitability areas of kermes oak (Quercus coccifera L.) in the levant under climate change. Reg. Environ. Change 17, 143–156. https://doi.org/10.1007/s10113-016-0987-2 (2017) Kumar, D., Rawat, S. & Joshi, R. Predicting the current and future suitable habitat distribution of the medicinal tree Oroxylum indicum (L.) Kurz in India. J. Appl. Res. Med. Aromat. Plants 23, 100309. https://doi.org/10.1016/j.jarmap.2021.100309 (2021) Qin, A. L. et al. MaxEnt modeling for predicting impacts of climate change on the potential distribution of Thuja sutchuenensis Franch., An extremely endangered conifer from southwestern China. Glob. Ecol. Conserv. 10, 139–146. https://doi.org/10.1016/j.gecco.2017.02.004 (2017) Thuiller, W., Lavore, S., Araújo, M. B., Sykes, M. T. & Prentice, I. C. Climate change threats to plant diversity in Europe. Natl. Acad. Sci. 102, 8245–8250. https://doi.org/10.1073/pnas.0409902102 (2005) IUCN. Avaliable online: The IUCN Red List of Threatened Species. Version 2021–3. https://www.iucnredlist.org (20 December 2021) A Short History of the World 669 (Penguin Books Risk identification of Türkiye’s coasts with the coastal vulnerability indicator Possible effects of sea level change due to anthropogenic climate change on sinop peninsula Implications for climate and sea level of revised IPCC emissions scenarios Sea-level rise and coastal forest retreat on the West coast of Florida Download references This research was funded by Turkish Scientific Council (TÜBİTAK) 2209 project is a scholar in the field of “Sustainable Forestry and Forest Disasters” within the scope of YÖK 100/2000 project) Ayse Gul Sarikaya and Almira Uzun performed background research and designed the study Ayse Gul Sarikaya and Funda Dila Turan obtained the data and analysed them The modelling results were reviewed by Almira Uzun All authors discussed the results and commented on the manuscript The order of the authors is based on the level of their contribution The authors declare no competing interests Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Download citation DOI: https://doi.org/10.1038/s41598-024-68683-2 Anyone you share the following link with will be able to read this content: a shareable link is not currently available for this article Sign up for the Nature Briefing: Anthropocene newsletter — what matters in anthropocene research Baltimore County police have identified the remains of a man whose body was found in Arbutus County police said officers were called Sunday to the 4700 block of Aldgate Green where a man’s body was found near an apartment complex Police said officials identified the man Thursday as Herson N and said homicide detectives are investigating Anyone with information is asked to call police at 410-887-INFO